^
    Back
    Association details:
    Biomarker:PD-L1 elevation
    Cancer:Lung Cancer
    Drug Class:Immunotherapy
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Future Oncol
    Title:

    Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis

    Published date:
    12/07/2021
    Excerpt:
    High sPD-L1 was significantly associated with worse OS (hazard ratio [HR] = 2.20; 95% CI: 1.59-3.05; p < 0.001) and PFS (HR = 2.42; 95% CI: 1.72-3.42; p < 0.001) in patients treated with immune checkpoint inhibitors (ICIs)….sPD-L1 is a potential predictive biomarker of lung cancer.
    DOI:
    https://doi.org/10.2217/fon-2021-0641